QQQ   431.56 (+0.12%)
AAPL   168.55 (-2.40%)
MSFT   416.27 (+0.64%)
META   501.67 (+0.29%)
GOOGL   154.55 (-0.20%)
AMZN   183.99 (+0.20%)
TSLA   157.92 (-2.20%)
NVDA   871.24 (+1.31%)
AMD   163.60 (+2.05%)
NIO   3.81 (-2.06%)
BABA   69.32 (-1.84%)
T   16.03 (-1.29%)
F   12.08 (-1.23%)
MU   121.01 (-0.30%)
GE   154.82 (+0.73%)
CGC   7.00 (+0.29%)
DIS   114.09 (+1.01%)
AMC   2.72 (+10.12%)
PFE   25.86 (-0.19%)
PYPL   63.83 (+0.50%)
XOM   118.80 (-0.74%)
QQQ   431.56 (+0.12%)
AAPL   168.55 (-2.40%)
MSFT   416.27 (+0.64%)
META   501.67 (+0.29%)
GOOGL   154.55 (-0.20%)
AMZN   183.99 (+0.20%)
TSLA   157.92 (-2.20%)
NVDA   871.24 (+1.31%)
AMD   163.60 (+2.05%)
NIO   3.81 (-2.06%)
BABA   69.32 (-1.84%)
T   16.03 (-1.29%)
F   12.08 (-1.23%)
MU   121.01 (-0.30%)
GE   154.82 (+0.73%)
CGC   7.00 (+0.29%)
DIS   114.09 (+1.01%)
AMC   2.72 (+10.12%)
PFE   25.86 (-0.19%)
PYPL   63.83 (+0.50%)
XOM   118.80 (-0.74%)
QQQ   431.56 (+0.12%)
AAPL   168.55 (-2.40%)
MSFT   416.27 (+0.64%)
META   501.67 (+0.29%)
GOOGL   154.55 (-0.20%)
AMZN   183.99 (+0.20%)
TSLA   157.92 (-2.20%)
NVDA   871.24 (+1.31%)
AMD   163.60 (+2.05%)
NIO   3.81 (-2.06%)
BABA   69.32 (-1.84%)
T   16.03 (-1.29%)
F   12.08 (-1.23%)
MU   121.01 (-0.30%)
GE   154.82 (+0.73%)
CGC   7.00 (+0.29%)
DIS   114.09 (+1.01%)
AMC   2.72 (+10.12%)
PFE   25.86 (-0.19%)
PYPL   63.83 (+0.50%)
XOM   118.80 (-0.74%)
QQQ   431.56 (+0.12%)
AAPL   168.55 (-2.40%)
MSFT   416.27 (+0.64%)
META   501.67 (+0.29%)
GOOGL   154.55 (-0.20%)
AMZN   183.99 (+0.20%)
TSLA   157.92 (-2.20%)
NVDA   871.24 (+1.31%)
AMD   163.60 (+2.05%)
NIO   3.81 (-2.06%)
BABA   69.32 (-1.84%)
T   16.03 (-1.29%)
F   12.08 (-1.23%)
MU   121.01 (-0.30%)
GE   154.82 (+0.73%)
CGC   7.00 (+0.29%)
DIS   114.09 (+1.01%)
AMC   2.72 (+10.12%)
PFE   25.86 (-0.19%)
PYPL   63.83 (+0.50%)
XOM   118.80 (-0.74%)
Free Trial
LON:ROQ

Roquefort Therapeutics (ROQ) Share Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)
Free ROQ Stock Alerts
GBX 4.53
-0.02 (-0.37%)
(As of 12:22 PM ET)
Compare
Today's Range
4.53
▼
4.60
50-Day Range
4
▼
9.25
52-Week Range
3.90
▼
9.50
Volume
429,545 shs
Average Volume
322,713 shs
Market Capitalization
£5.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades
ROQ stock logo

About Roquefort Therapeutics Stock (LON:ROQ)

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.

ROQ Stock Price History

ROQ Stock News Headlines

April 5, 2024 | msn.com
UK Stocks: Here’s Why Roquefort (ROQ) Share Price is Crashing
March 11, 2024 | lse.co.uk
Roquefort celebrates "significant milestones" in cancer research
April 16, 2024 | InvestorPlace (Ad)
A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
March 11, 2024 | uk.investing.com
Roquefort Therapeutics reveals progress with liver and colorectal cancer programmes
December 21, 2023 | seekingalpha.com
NBSE NeuBase Therapeutics, Inc.
November 6, 2023 | lse.co.uk
Roquefort Therapeutics MK cell programme shows positive results
September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as eyes commercial deals
September 27, 2023 | proactiveinvestors.com
Roquefort Therapeutics preparing targets for clinic as it eyes commercial deals
April 16, 2024 | InvestorPlace (Ad)
A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
August 17, 2023 | finance.yahoo.com
Roquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patents
August 9, 2023 | finance.yahoo.com
Roquefort Therapeutics making headway with siRNA
June 29, 2023 | proactiveinvestors.com
Roquefort Therapeutics highlights significant progress at AGM
June 22, 2023 | proactiveinvestors.com
Roquefort Therapeutics hails significant pre-clinical results
June 22, 2023 | marketwatch.com
Roquefort Therapeutics Makes Progress on Cancer Treatment
June 16, 2023 | finance.yahoo.com
Roquefort Therapeutics returns to the market with new study data
June 13, 2023 | marketwatch.com
Roquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive Results
June 7, 2023 | marketwatch.com
Roquefort Therapeutics Resumes Trading After Publishing 2022 Results
June 5, 2023 | proactiveinvestors.com
Roquefort Therapeutics eyes second half progress
March 13, 2023 | proactiveinvestors.com
Roquefort Therapeutics has no exposure to SVB
March 8, 2023 | proactiveinvestors.com
Roquefort Therapeutics says new mRNA platform "fits very well"
March 8, 2023 | proactiveinvestors.com
Roquefort develops a fifth programme using a technology pioneered by Moderna and BioNTech
March 6, 2023 | proactiveinvestors.com
Roquefort Therapeutics establishes scientific advisory board
February 22, 2023 | lse.co.uk
Roquefort Thera Regulatory News
February 21, 2023 | barrons.com
Roquefort Therapeutics PLC
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks Randox diagnostic deal
February 20, 2023 | proactiveinvestors.com
Roquefort Therapeutics inks first strategic licensing deal with diagnostics firm Randox
January 26, 2023 | finance.yahoo.com
Roquefort Therapeutics demonstrates initial safety in two antibody programmes
See More Headlines
Receive ROQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:ROQ
CUSIP
N/A
CIK
N/A
Web
www.roquefortinvest.com
Phone
44 20 3290 9339
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-1,640,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-33.20%
Return on Assets
-19.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.66
Quick Ratio
3.07

Sales & Book Value

Annual Sales
£637.00
Price / Sales
9,225.00
Cash Flow
GBX 3.04 per share
Price / Cash Flow
1.49
Book Value
GBX 5 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
129,150,000
Free Float
N/A
Market Cap
£5.88 million
Optionable
Not Optionable
Beta
-0.03
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Stephen Paul West B.Com (Age 52)
    CA, Executive Chairman
    Comp: $118.31k
  • Mr. Trevor Ajanthan Reginald (Age 52)
    CEO & Executive Director
    Comp: $284.1k
  • Prof. Martin J. Evans FRS (Age 83)
    Group Chief Scientific Officer & Executive Director
    Comp: $101.22k
  • Dr. Emma Morris
    Head of Pre-Clinical Research

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ROQ Stock Analysis - Frequently Asked Questions

How have ROQ shares performed in 2024?

Roquefort Therapeutics' stock was trading at GBX 7.25 at the beginning of the year. Since then, ROQ stock has decreased by 37.5% and is now trading at GBX 4.53.
View the best growth stocks for 2024 here.

How do I buy shares of Roquefort Therapeutics?

Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:ROQ) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The #1 Crypto for 2024
InvestorPlace
The Greatest Bull Market in Crypto History…
Weiss Ratings